Skip to main content
This CBD Super-Strain Play Could Be a Moonshot
One little-known stock just inked a deal with a big-name corporation. This virtually unknown company could be the biggest bargain buy of 2021.

NYSE:BDX - Becton, Dickinson and Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $280.22
  • Forecasted Upside: 16.23 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$241.09
▼ -1.29 (-0.53%)
1 month | 3 months | 12 months
Get New Becton, Dickinson and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$280.22
▲ +16.23% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Becton, Dickinson and in the last 3 months. The average price target is $280.22, with a high forecast of $300.00 and a low forecast of $260.00. The average price target represents a 16.23% upside from the last price of $241.09.
Promising CBD Company Posts Red Hot IPO
A new research report indicates that this young IPO is beating out the industry's toughest competition, and it's takeover is just getting started.

Buy

The current consensus among 10 polled investment analysts is to buy stock in Becton, Dickinson and. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/24/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/22/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/20/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/18/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2021SVB LeerinkLower Price TargetMarket Perform$270.00 ➝ $260.00N/A
i
5/7/2021SVB LeerinkLower Price TargetMarket Perform$270.00 ➝ $260.00High
i
2/5/2021CitigroupBoost Price TargetNeutral$273.00 ➝ $280.00Low
i
2/4/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$275.00 ➝ $280.00Low
i
1/29/2021Raymond JamesBoost Price TargetOutperform$270.00 ➝ $282.00Low
i
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
i
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$265.00Medium
i
12/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$262.00 ➝ $297.00Medium
i
11/6/2020Morgan StanleyLower Price TargetEqual Weight$270.00 ➝ $262.00Low
i
10/12/2020Raymond JamesLower Price TargetOutperform$285.00 ➝ $270.00Low
i
10/2/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyMedium
i
Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/27/2020Morgan StanleyLower Price TargetEqual Weight$285.00 ➝ $270.00High
i
8/10/2020UBS GroupBoost Price TargetNeutral$265.00 ➝ $280.00Low
i
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$248.00 ➝ $285.00Low
i
8/7/2020Raymond JamesBoost Price TargetOutperform$265.00 ➝ $285.00Medium
i
7/15/2020SVB LeerinkBoost Price TargetMarket Perform$262.00 ➝ $277.00Medium
i
Rating by Richard Newitter at SVB Leerink LLC
7/9/2020BarclaysUpgradeEqual Weight ➝ Overweight$300.00Medium
i
7/2/2020William BlairReiterated RatingOutperformLow
i
Rating by B. Weinstein at William Blair
6/25/2020Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $248.00High
i
6/25/2020Raymond JamesLower Price TargetPositive ➝ Outperform$290.00 ➝ $265.00High
i
5/31/2020The Goldman Sachs GroupInitiated CoverageBuy$278.00Low
i
5/14/2020Piper SandlerBoost Price TargetOverweight$286.00 ➝ $296.00Low
i
5/12/2020KeyCorpReiterated RatingHoldLow
i
Rating by Matthew Mishan at KeyCorp
5/8/2020SVB LeerinkReiterated RatingMarket Perform$245.00 ➝ $262.00Low
i
5/8/2020CfraLower Price TargetHold$285.00 ➝ $278.00Medium
i
5/8/2020UBS GroupBoost Price TargetNeutral$260.00 ➝ $265.00Medium
i
5/8/2020Stifel NicolausBoost Price TargetBuy$265.00 ➝ $280.00Medium
i
5/8/2020Raymond JamesBoost Price TargetOutperform$283.00 ➝ $290.00Low
i
5/8/2020CitigroupBoost Price TargetNeutral$234.00 ➝ $260.00Low
i
5/8/2020Wells Fargo & CompanyReiterated RatingBuyLow
i
4/14/2020BarclaysReiterated RatingHold$266.00Low
i
4/8/2020SVB LeerinkLower Price TargetMarket Perform$269.00 ➝ $245.00High
i
4/8/2020Wells Fargo & CompanyLower Price TargetOverweight$279.00 ➝ $270.00High
i
4/1/2020Stifel NicolausLower Price TargetBuy$280.00 ➝ $265.00Medium
i
3/27/2020CitigroupLower Price TargetNeutral$260.00 ➝ $234.00Medium
i
3/27/2020Morgan StanleyLower Price TargetEqual Weight$271.00 ➝ $255.00Medium
i
3/4/2020CitigroupInitiated CoverageNeutral$260.00Medium
i
2/7/2020Morgan StanleyLower Price TargetHold ➝ Equal Weight$287.00 ➝ $271.00Medium
i
2/7/2020Wells Fargo & CompanyLower Price TargetOverweight$285.00 ➝ $279.00Medium
i
Rating by Larry Biegelsen at Wells Fargo & Company
2/7/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$288.00 ➝ $283.00Medium
i
2/6/2020CowenDowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00High
i
Rating by Josh Jennings at Cowen Inc
2/6/2020Piper SandlerBoost Price TargetOverweight$279.00 ➝ $285.00High
i
2/6/2020CfraDowngradeBuy ➝ Hold$304.00 ➝ $285.00High
i
2/3/2020CowenReiterated RatingOutperform ➝ Outperform$255.00 ➝ $305.00High
i
1/22/2020KeyCorpBoost Price TargetOverweight$284.00 ➝ $298.00Low
i
1/8/2020BarclaysDowngradeOverweight ➝ Equal Weight$275.00Low
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$285.00 ➝ $300.00Low
i
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$261.00 ➝ $287.00Low
i
12/16/2019Stifel NicolausBoost Price TargetBuy$275.00 ➝ $295.00Low
i
11/13/2019KeyCorpLower Price TargetOverweight$262.00 ➝ $256.00Medium
i
9/6/2019Wells Fargo & CompanyBoost Price TargetOutperform$270.00 ➝ $290.00N/A
i
9/5/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by Larry Biegelsen at Wells Fargo & Company
8/6/2019Piper Jaffray CompaniesLower Price TargetOverweight$267.00 ➝ $266.00Medium
i
7/16/2019Morgan StanleyBoost Price TargetEqual Weight$250.00 ➝ $261.00Low
i
6/28/2019Raymond JamesBoost Price TargetStrong-Buy$265.00 ➝ $288.00Low
i
5/13/2019Wells Fargo & CompanyLower Price TargetOutperform$280.00 ➝ $265.00Low
i
5/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$266.00Low
i
5/10/2019BMO Capital MarketsLower Price TargetMarket Perform$272.00 ➝ $270.00Low
i
5/10/2019Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $250.00High
i
5/10/2019UBS GroupLower Price TargetNeutral$265.00 ➝ $250.00High
i
5/10/2019KeyCorpReiterated RatingPositive ➝ Overweight$273.00 ➝ $262.00High
i
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00Low
i
Rating by Kristen Stewart at Barclays PLC
3/19/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$290.00 ➝ $280.00Medium
i
2/5/2019Piper Jaffray CompaniesBoost Price TargetOverweight$274.00Low
i
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00Low
i
1/2/2019CitigroupLower Price TargetBuy ➝ Buy$279.00 ➝ $256.00Low
i
12/6/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$280.00Medium
i
11/27/2018UBS GroupInitiated CoverageNeutral$260.00Medium
i
11/13/2018CitigroupLower Price TargetBuy ➝ Buy$289.00 ➝ $279.00Low
i
11/8/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$264.00 ➝ $273.00Medium
i
11/8/2018BarclaysSet Price TargetHold$260.00Medium
i
Rating by Kristen Stewart at Barclays PLC
11/7/2018Wells Fargo & CompanyLower Price TargetOutperform$290.00 ➝ $280.00High
i
11/6/2018Piper Jaffray CompaniesLower Price TargetOverweight$250.00Medium
i
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$278.00High
i
10/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $280.00High
i
9/6/2018Wells Fargo & CompanyBoost Price TargetOutperform$275.00 ➝ $290.00Low
i
8/8/2018CitigroupBoost Price TargetBuy ➝ Buy$274.00 ➝ $283.00Medium
i
8/3/2018Royal Bank of CanadaReiterated RatingHold$248.00Low
i
8/3/2018KeyCorpReiterated RatingBuy$264.00Low
i
6/21/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$175.00Medium
i
4/10/2018CitigroupUpgradeNeutral ➝ Buy$237.00 ➝ $251.00Low
i
3/5/2018BMO Capital MarketsInitiated CoverageMarket Perform$249.00Low
i
2/7/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$245.00 ➝ $250.00Low
i
2/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$223.00 ➝ $260.00Low
i
1/19/2018Bank of AmericaReiterated RatingBuy ➝ Buy$260.00Medium
i
1/5/2018CitigroupUpgradeSell ➝ NeutralLow
i
1/5/2018KeyCorpInitiated CoverageOverweight ➝ Overweight$260.00Low
i
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$245.00Medium
i
12/29/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$239.00 ➝ $260.00Low
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
12/14/2017ArgusBoost Price TargetAverage ➝ Buy$235.00Low
i
11/3/2017Stifel NicolausReiterated RatingBuy$245.00N/A
i
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$205.00 ➝ $245.00N/A
i
11/3/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$210.00 ➝ $230.00N/A
i
10/25/2017Royal Bank of CanadaReiterated RatingHold$210.00N/A
i
10/24/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Positive$225.00 ➝ $235.00N/A
i
9/22/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$225.00Low
i
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$213.00High
i
8/14/2017CowenReiterated RatingBuy$230.00Low
i
8/10/2017BarclaysReiterated RatingEqual Weight$205.00 ➝ $210.00Low
i
8/9/2017Stifel NicolausReiterated RatingBuyLow
i
7/21/2017Bank of AmericaReiterated RatingBuy$200.00 ➝ $225.00Medium
i
7/10/2017CowenReiterated RatingOutperform$200.00 ➝ $230.00Low
i
6/30/2017Raymond JamesUpgradeOutperform ➝ Strong-Buy$210.00 ➝ $180.00Low
i
4/24/2017Evercore ISIUpgradeIn-Line ➝ Outperform$186.00 ➝ $200.00High
i
4/13/2017Royal Bank of CanadaReiterated RatingHold$177.00Low
i
3/29/2017Jefferies Financial GroupReiterated RatingBuy$200.00Low
i
1/6/2017Royal Bank of CanadaReiterated RatingHold$177.00N/A
i
1/5/2017Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$200.00 ➝ $180.00N/A
i
1/5/2017UBS GroupDowngradeStrong-Buy ➝ OutperformN/A
i
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$190.00 ➝ $175.00N/A
i
11/21/2016SVB LeerinkReiterated RatingMarket Perform$180.00 ➝ $185.00N/A
i
11/18/2016UBS GroupReiterated RatingBuy$195.00N/A
i
11/4/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$197.00 ➝ $189.00N/A
i
10/21/2016ArgusReiterated RatingBuy$185.00N/A
i
Rating by David Toung at Argus
9/23/2016CitigroupDowngradeNeutral ➝ Sell$167.00 ➝ $165.00N/A
i
8/16/2016CowenReiterated RatingOutperform$185.00N/A
i
8/9/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Richard Newitter at SVB Leerink LLC
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/5/2016UBS GroupBoost Price TargetBuy$182.00 ➝ $195.00N/A
i
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$190.00 ➝ $192.00N/A
i
7/12/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Derik De Bruin at Bank of America Co.
6/12/2016ArgusReiterated RatingBuyN/A
i
Rating by David Toung at Argus
6/1/2016Evercore ISIDowngradeBuy ➝ HoldN/A
i
5/18/2016SVB LeerinkReiterated RatingHold$175.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
(Data available from 5/18/2016 forward)
Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $241.09
$241.04
$245.29

50 Day Range

MA: $248.78
$239.39
$260.94

52 Week Range

Now: $241.09
$219.50
$284.97

Volume

976,657 shs

Average Volume

1,352,495 shs

Market Capitalization

$70.11 billion

P/E Ratio

88.31

Dividend Yield

1.37%

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Becton, Dickinson and?

The following Wall Street sell-side analysts have issued reports on Becton, Dickinson and in the last twelve months: Barclays PLC, Citigroup Inc., Morgan Stanley, Piper Sandler, Raymond James, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BDX.

What is the current price target for Becton, Dickinson and?

9 Wall Street analysts have set twelve-month price targets for Becton, Dickinson and in the last year. Their average twelve-month price target is $280.22, suggesting a possible upside of 15.6%. Barclays PLC has the highest price target set, predicting BDX will reach $300.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $260.00 for Becton, Dickinson and in the next year.
View the latest price targets for BDX.

What is the current consensus analyst rating for Becton, Dickinson and?

Becton, Dickinson and currently has 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDX will outperform the market and that investors should add to their positions of Becton, Dickinson and.
View the latest ratings for BDX.

What other companies compete with Becton, Dickinson and?

How do I contact Becton, Dickinson and's investor relations team?

Becton, Dickinson and's physical mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier's listed phone number is 201-847-6800. The official website for Becton, Dickinson and is www.bd.com.

Promising CBD Company Posts Red Hot IPO
A new research report indicates that this young IPO is beating out the industry's toughest competition, and it's takeover is just getting started.